Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Disaggregation of Revenue [Abstract]

Schedule of Revenue Disaggregated by Customer Type

The following table presents the Company's revenue disaggregated by customer type (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Pharma tests and services (1)	$	13,137	$	15,698	$	37,754	$	38,707
Enterprise sales		650		5,264		5,430		21,194
Population sequencing		234		4,431		7,755		7,211
Clinical diagnostic		384		271		1,161		583
Other		90		45		203		119
Total revenue	$	14,495	$	25,709	$	52,303	$	67,814

(1) Includes related party revenue of $1.1 million and $3.5 million for the three and nine months ended September 30, 2025,respectively.

Schedule of Contract Assets and Liabilities

The opening and closing balances of receivables and contract liabilities from contracts with customers are shown below (in thousands). Contract assets were immaterial for all periods presented.

	September 30, 2025		December 31, 2024
Opening balances:
Accounts receivable, net	$	8,140	$	17,730
Short-term contract liabilities	$	3,100	$	3,288
Long-term contract liabilities (included in other long-term liabilities)		—		3,928
Total contract liabilities	$	3,100	$	7,216
Closing balances:
Accounts receivable, net	$	14,376	$	8,140
Short-term contract liabilities		1,457		3,100
Total contract liabilities	$	1,457	$	3,100